Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2611 to 2625 of 9098 results

  1. Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]

    In development Reference number: GID-TA10089 Expected publication date:  15 November 2017

    Technology appraisal guidance
    In development

  2. Encaleret for treating autosomal dominant hypocalcaemia type 1 in people 16 years and over [GID-TA12008]

    Awaiting development Reference number: GID-TA12008 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Lonapegsomatropin for treating growth hormone deficiency in people 3 to 17 years [GID-TA12013]

    Awaiting development Reference number: GID-TA12013 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Lemborexan for treating insomnia [GID-TA12011]

    Awaiting development Reference number: GID-TA12011 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Beremagene geperpavec for treating skin wounds associated with dystrophic epidermolysis bullosa [ID3959]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 17 July 2026.

    Technology appraisal guidance
    In consultation

  6. Beremagene geperpavec for treating skin wounds associated with dystrophic epidermolysis bullosa [ID3959]

    In development Reference number: GID-TA10868 Expected publication date:  18 November 2026

    Technology appraisal guidance
    In development

  7. Fenfluramine for treating seizures associated with Dravet syndrome in people under 2 years

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  8. Secukinumab for treating moderate to severe hidradenitis suppurativa in people 12 to 17 years

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  9. Mirikizumab for treating moderately to severely active ulcerative colitis in people 2 to 17 years

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  10. Bee venom immunotherapy for generalised or systemic IgE-mediated allergic reactions to bee venom

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  11. Wasp venom immunotherapy for treating wasp venom allergy

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  12. Suspected sepsis: recognition, diagnosis and early management - procalcitonin testing

    In development Reference number: GID-NG10467 Expected publication date:  11 September 2026

    NICE guideline
    In development

  13. Venglustat for treating Fabry disease

    Awaiting development Reference number: GID-TA12452 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Orforglipron for managing overweight and obesity in people 12 to 17 years

    Awaiting development Reference number: GID-TA12451 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Divarasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer

    Awaiting development Reference number: GID-TA12450 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development